TP53 and cancer: Many of these studies evaluate the effect of AZD1775 on p53-deficient cancers (NCT01164995, NCT02101775, NCT03668340, and NCT01849146), BRCA-deficient cancers (NCT04439227), and/or in combination with DNA-damaging agents (NCT02513563, NCT01164995, NCT02101775, and NCT03579316, NCT02101775, NCT03668340, NCT02546661, NCT03345784, NCT02095132, and NCT01849146).